Nephrology News
FDA Approves Sunitinib for Adjuvant Treatment of RCC
At 5 years, 59.3% of patients treated with sunitinib were free from recurrence versus 51.3% who received placebo.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/